Recursion Pharmaceuticals (RXRX) Assets Average (2021 - 2026)

Recursion Pharmaceuticals has reported Assets Average for 6 years, with the latest figure at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 2.17% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 2.17% YoY), and the FY2025 full-year result was $1.5 billion, up 39.03% from the prior year.
• Assets Average for Q1 2026 stood at $1.4 billion, down from $1.4 billion in the prior quarter.
• The five-year high for Assets Average was $1.4 billion in Q4 2025, with the low at $605.8 million in Q1 2024.
• Historically, Assets Average has averaged $897.8 million across 5 years, with a median of $672.3 million in 2022.
• Annual changes were most pronounced in 2022 — Assets Average surged 135.69% — and 2024, when it slipped 8.81%.
• Recursion Pharmaceuticals' Assets Average stood at $656.4 million in 2022, then slipped by 2.16% to $642.3 million in 2023, then soared by 69.33% to $1.1 billion in 2024, then jumped by 32.12% to $1.4 billion in 2025, then dropped by 2.09% to $1.4 billion in 2026.
• The last three Assets Average figures came in at $1.4 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.